Please assess the completion status of the following clinical trial:

Trial Title: First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed acute lymphoblastic or biphenotypic leukemia (karyotypic or molecular evidence of Ph)~* Ages of 15-65 years~* Eastern Cooperative Oncology Group performance status of 0-2~* Adequate renal (serum creatinine less than 2 mg/dl, unless considered due to leukemia) and hepatic (serum bilirubin less than 3 mg/dl, unless considered due to leukemia) functions~* Adequate cardiac status (New York Heart Association Class less than or equal to 2)~* Signed informed consent~Exclusion Criteria:~* Pregnant and lactating women will not be eligible. Women of childbearing potential should have a negative pregnancy test prior to entering on the study.~* Active cardiac dysfunction (New York Heart Association Class more than or equal to 3), uncontrolled angina, myocardial infarction (within 6 months), congenital long QT syndrome, any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia or ventricular fibrillation), or prolonged QTc interval on pre-entry electrocardiogram (more than 470 msec)~* Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia~* Patients with severe medical conditions that in the view of the investigator prohibits participation in the study~* Treatment with any other investigational antileukemic agents in the last 30 days before study entry

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Modified Hyper-CVAD + Dasatinib (Type: EXPERIMENTAL): Dasatinib: 100 mg once daily, PO, for 4 weeks Cyclophosphamide: 300 mg/m2, IV, every 12 hours, days 1\~3 Vincristine: 1.4 mg/m2/day (maximum 2 mg/day), IV, days 4 \& 11 Daunorubicin: 45 mg/m2/day, IV, days 4 \& 11 Dexamethasone: 40 mg/day, IV, days 1\~4 \& days 11\~14 Cytarabine: 2 g/m2, IV, every 12 hours, days 1\~5 Mitoxantrone: 12 mg/m2/day, IV, days 1\~2

Based on this trial design, predict the completion outcome and termination type (if applicable).